^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:purinostat (HDAC1 inhibitor, HDAC2b inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ICML 2023
    Title:

    ACTIVITY AND SAFETY OF PRECLINICAL AND A PHASE 1 STUDY OF PURINOSTAT MESYLATE, A UNIQUELY POTENT AND SELECTIVE HDAC I/IIB INHIBITOR IN RELAPSED OR REFRACTORY LYMPHOMA

    Published date:
    06/09/2023
    Excerpt:
    ...multiple cell lines, xenograft mouse models of diffuse large B-cell lymphoma (DLBCL) were used to evaluate the PM activity and mechanism in vitro and in vivo…we found that PM showed strong inhibitory activity against TP53-mutated DLBCL cell lines….Preclinical studies have also confirmed the potent anti-tumor activity of PM in DLBCL.
    DOI:
    https://doi.org/10.1002/hon.3165_654